An early Center for Disease Control and Prevention (CDC) analysis revealed that the latest COVID-19 vaccines are 54% effective in preventing symptomatic infections among adults, offering protection against the dominant JN.1 subvariant.
Researchers, through the CDC's program offering free tests to the uninsured, collected data on individuals with COVID-19-like symptoms.
A man receives a dose of Comirnaty Omicron XBB 1.5 Pfizer vaccine for COVID-19 at a pharmacy in Ajaccio, on October 5, 2023, during a new COVID-19 vaccination campagin on the French Mediterranean island of Corsica.
Evaluating COVID-19 Vaccine Effectiveness
The data for the recent analysis originated from tests conducted at CVS Pharmacy and Walgreens locations between September 2023 and January 2024. To assess the effectiveness of the updated COVID-19 vaccines administered during the fall and winter seasons, researchers focused on patients aged 18 and above who exhibited symptoms resembling COVID-19.
The vaccines demonstrated a 54% effectiveness in preventing symptomatic infections, with an early analysis from the Centers for Disease Control and Prevention (CDC) revealing protection against the dominant JN.1 subvariant.
The study involved comparing individuals who tested negative for COVID-19, forming a control group, against those who tested positive. This comparison encompassed evaluating the occurrence of self-reported symptoms as well as examining the history of infection and immunization.
Among the 9,222 tests considered eligible for analysis, the vaccines exhibited a 54% effectiveness rate in adults. The protection offered by the updated monovalent COVID-19 vaccines extended to infections caused by both the JN.1 subvariant and XBB-related lineages, as indicated by the analysis.
Despite the promising findings, the report acknowledged certain limitations within the analysis. The reliance on self-reported information regarding patient history of immunization, underlying medical conditions and infection, introduces the potential for recall bias.
Additionally, the results were derived from a population that actively chose to undergo SARS-CoV-2 testing, implying the presence of additional biases that may impact the data.
While the updated vaccines were designed to target the XBB.1.5 omicron subvariant, health officials anticipated that the dominant strains prevailing at the time of vaccination would maintain sufficient relatedness for the shots to remain effective.
CDC Monitors JN.1 Subvariant and Highlights Vaccine Urgency
The JN.1 subvariant has emerged as the fastest-growing variant in the United States, representing an estimated 15% to 29% of circulating variants, surpassing its predecessor BA.2.86. The CDC notes that BA.2.86, which stemmed from the BA.2 lineage and was once prevalent, now accounts for approximately 1.6% of circulating variants.
The JN.1 variant is characterized by being more transmissible, but the overall public health risk for severe illness remains low, with the CDC closely monitoring its impact during the winter and holiday season.
While JN.1's proportion of cases is increasing, there is no evidence of a significant rise in hospitalizations or severity of illness. Concerns about immune evasion were raised with BA.2.86 due to its high mutation count, but the CDC suggests that updated COVID-19 vaccines are expected to enhance protection against both JN.1 and BA.2.86.
Lagging vaccination rates for COVID-19, influenza, and respiratory syncytial virus (RSV) pose challenges, urging health officials to emphasize vaccinations to prevent another severe respiratory virus season.
It is emphasized that getting vaccinated against COVID-19 not only protects against reinfection but also reduces the risk of long COVID, highlighting the universal recommendation for individuals aged 6 months and older to receive the vaccine promptly, aligning with a similar approach for the flu vaccine.
RELATED ARTICLE: Enhanced COVID-19 Protection: 10 Things To Know About 2023-2024 mRNA Vaccine Update
Check out more news and information on COVID-19 in Science Times.
